Pfizer delivered a Q1 beat but the stock ended the week almost flat — and short sellers spent the week adding to positions at a pace that has been building steadily since early April.
Short interest is the story that stands out this week, even if the absolute level remains modest. SI climbed to 2.53% of the free float on May 5, up from 2.13% at the start of April — a 19% rise in the position over roughly five weeks. The one-week gain of 6.3% is the most aggressive weekly build in that stretch. The direction of travel is clear: bears have been adding through the Q1 results rather than covering into them. The ORTEX short score has also ticked higher, reaching 34.4 on May 5 versus 33.0 a week earlier, putting short positioning in the 65th percentile relative to the broader market.
The borrowing market offers little alarm, however. Cost to borrow runs at just 0.47% annually — cheap by any measure — and borrow availability remains extremely loose. That combination tells a different story from the raw SI move: this is systematic pressure, not an aggressive squeeze setup. Availability is nowhere near stressed territory, meaning new short positions are easy to initiate and existing ones cheap to hold. Options positioning is similarly relaxed. The put/call ratio at 0.87 is barely above its 20-day average of 0.87, with a z-score of just 0.45 — options traders show no particular skew toward downside protection right now.
The Street is cautiously positioned, with more neutrals than conviction in either direction. Most of the April and early May analyst activity involved target nudges rather than rating changes. Citigroup raised its target to $27 following the Q1 print on April 29, while maintaining Neutral. Morgan Stanley edged its target to $28 and also held at Equal-Weight. BofA moved in the opposite direction earlier in April, trimming to $26 while staying Neutral. The mean price target of $29.11 implies roughly 10% upside from the current $26.45 — not a ringing endorsement, but not bearish either. CICC initiated at Outperform with a $33 target in mid-April, one of the more bullish fresh calls in the group. Valuation looks undemanding: the P/E has compressed to around 9x trailing earnings, and EV/EBITDA has drifted down modestly over the past month to just under 8x. The forward EPS trajectory, meanwhile, ranks in the 97th percentile for year-over-year increase — the highest-scoring factor in the snapshot — suggesting the earnings revision cycle is running strongly positive even as the stock has fallen 6.6% over the past month.
The bull case rests on that revision momentum, a $60 billion annual revenue base, and a dividend yield running near 6.6% — dividend score ranks in the 94th percentile. The bear case centres on gross-to-net headwinds on key products like Vyndaqel and Ibrance, where the market may be underestimating the drag on reported revenue. Peer performance was mixed on the week: BMY fell 2.2% and ZTS dropped 3.5%, while JNJ was roughly flat. PFE's near-flat week looks relatively resilient against that backdrop.
The next earnings date is July 28. Between now and then, the key data points to watch are whether short interest continues its steady rebuild — particularly if it breaks above the 3% free-float threshold — and whether the EPS revision momentum translates into forward estimate upgrades that close the gap to analyst price targets.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
